Transplantation Product Pipeline Shows High Level of Innovation, States GBI Research in Its Report Available at MarketPublishers.com22 Jan 2018 • by Natalie Aster
LONDON – In 2015, the number of organ transplantations performed from pole to pole totaled up to 127,000, an upsurge of 5.8% YoY; with 33,000 of these procedures taking place across the EU and 32,000 in the USA. Close to 60% of these were kidney transplants, with hepatic, cardiac, pulmonary, pancreas and intestinal transplantations being the other most widespread procedures. In case a graft is transplanted from a genetically non-identical individual, the immune system of the recipient recognises the donor organ as foreign.
This results in an anti-donor immune response which involves T cells attacking the novel tissue, growing in number, and drawing more immune cells to the transplant area to eliminate this foreign body. In accordance with the incompatibility nature and the immunologic response, and the acute or chronic transplant rejection of transplanted organs can take place.
Alternatively, if the graft is comprised of hematopoietic stem cells (HSCs) or immune cells, there is a risk of them mounting an immunologic response against the organ receiver, referred to as graft versus host disease. There is a selection of safe pharmacological therapies for acute rejections, but long-run treatment modes are still unsatisfactory.
As against the total immunology pipeline, the transplantation pipeline is composed of only 244 products. Meantime, of a total of 145 pipeline products with a disclosed molecular target, there are 65 first-in-class products acting upon 63 individual first-in-class targets. This demonstrates that a strong degree of innovation in this pipeline.
Topical research study “Frontier Pharma: Transplantation Therapeutics - A Highly Innovative Pipeline with a Range of Adaptive and Innate Immune-Targeting Programs Focusing on Graft-Versus-Host Disease and Kidney Transplantation” drawn up by GBI Research drawn up by GBI Research gives an all-encompassing examination of the transplantation therapeutic landscape from a global level.
The publication presents an insightful discussion of the present-day clinical and commercial landscape by taking a look at disease symptoms, diagnosis, etiology and pathophysiology, therapy modalities for the rejection of transplants. The study sheds light on the leading marketed products and current unmet needs. It keeps track of the trends in pipeline innovation by evaluating therapies based on development stage, molecular target and molecule type. The research report assesses and ranks the therapeutic potential of first-in-class targets in the pipeline according to their clinical potential. Furthermore, it discusses first-in-class pipeline products that were not involved in co-development and licensing deals before, and which potentially may bring investment opportunities.
A complete collection of the publisher’s research publications is at hand in GBI Research catalogue.